Viking Therapeutics price target lowered to $70 from $120 at Maxim
Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...
Has the Bubble Burst for Viking Therapeutics Stock?
And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...
Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates
Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...
Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials
Viking thinks the oral alternative offers a smooth transition from the subcutaneous form and might appeal to individuals reluctant about injectable therapies. The business completed an End-of-Phase 2 ...
What’s next for hot biotech stock Viking Therapeutics? Here’s how the company can scale up.
Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising ...
Viking stock slides 8% following Q4 report, pipeline update
Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...
Viking Therapeutics initiated with a Neutral at Citi
Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...